bs-3807R **[Primary Antibody]**

PLAA Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 9373 **SWISS:** Q9Y263

Target: PLAA

Immunogen: KLH conjugated synthetic peptide derived from human Phospholipase A2 activator protein: 101-200/795.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Phospholipase A2 activator protein (PLAP), activates PLA2 (phospholipase A2 enzyme) and is an important mediator of eicosanoid generation. Also known as a pro-inflammatory agent, PLAP has been found in inflamed tissues and synovial fluid from patients with rheumatoid arthritis. As such, it is believed to play an important role in the regulation of inflammatory diseases. The formation of PLAP can be stimulated by IL-1 beta and TNF-alpha.

Applications: **WB** (1:500-2000)
IHC-P (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse, Rat, Rabbit, Pig, Cow, Dog, Horse)

Predicted MW.: 87 kDa

Subcellular Location: Nucleus

SELECTED CITATIONS

- **[IF=3.71]** Rosing, Katharina, et al. Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis. 2013 Sep;230(1):164-70. WB ;="Human, Mouse". 23958269
- **[IF=2.9]** Hong-Yun Nie. et al. Moxifloxacin plus Cordyceps polysaccharide ameliorate intestinal barrier damage due to abdominal infection via anti-inflammation and immune regulation under simulated microgravity. LIFE SCI SPACE RES. 2024 Nov;: WB ;Rat. 10.1016/j.lssr.2024.11.005